Vertex Pharmaceuticals (NASDAQ:VRTX) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Vertex Pharmaceuticals (NASDAQ:VRTX) issued its quarterly earnings data on Monday. The pharmaceutical company reported $4.73 earnings per share for the quarter, missing analysts’ consensus estimates of $4.74 by ($0.01), FiscalAI reports. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. During the same period in the prior year, the company earned $4.52 earnings per share. The business’s revenue for the quarter was up 12.5% on a year-over-year basis.

Here are the key takeaways from Vertex Pharmaceuticals’ conference call:

• Positive Sentiment: Vertex reported second-quarter revenue of $3.3 billion, up 12% year over year, and raised 2026 revenue guidance to $13.1 billion–$13.2 billion. Management maintained its target of at least $500 million in non-CF revenue, while expecting operating expenses near the high end of its $5.65 billion–$5.75 billion range.
• Positive Sentiment: The cystic fibrosis franchise remained strong, with global revenue up 11% and ALYFTREK exceeding $1 billion in first-half revenue. Vertex highlighted rapid ALYFTREK adoption, including more than one-third of eligible patients in Germany and the U.K., and is pursuing additional approvals in younger children and rare mutations.
• Positive Sentiment: CASGEVY revenue rose to $76 million in the second quarter, up roughly 75% sequentially, while JOURNAVX revenue reached $50 million, up about 70% sequentially. CASGEVY patient initiations and infusions continued to build, and JOURNAVX prescriptions, prescriber adoption, hospital pathways, and payer coverage expanded significantly.
• Negative Sentiment: JOURNAVX’s rapid prescription growth is increasing use of Vertex’s patient support program because of remaining payer restrictions, delaying gross-to-net normalization until the first half of 2027. Management also cautioned that quarterly revenue may remain volatile as channel inventory and reimbursement patterns normalize.
• Positive Sentiment: Vertex is preparing for a potential November 30 FDA decision on povetacicept in IgA nephropathy, citing strong efficacy, monthly at-home auto-injector dosing, and a favorable safety profile. The company also advanced multiple pipeline programs, including completion of enrollment in studies of inaxaplin and VX-407, an upcoming type O islet-cell therapy trial, and the planned acquisition of Crinetics to establish a rare-endocrine franchise.

Vertex Pharmaceuticals Trading Down 1.3%

VRTX traded down $6.38 during midday trading on Monday, hitting $470.72. 1,508,725 shares of the company were exchanged, compared to its average volume of 1,462,815. The firm has a market capitalization of $119.47 billion, a price-to-earnings ratio of 27.92, a price-to-earnings-growth ratio of 2.15 and a beta of 0.29. The company’s 50 day simple moving average is $471.34 and its 200 day simple moving average is $460.44. Vertex Pharmaceuticals has a 1-year low of $362.50 and a 1-year high of $533.67.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Canaccord Genuity Group reduced their price objective on shares of Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating on the stock in a research note on Tuesday, May 5th. Truist Financial raised their target price on Vertex Pharmaceuticals from $542.00 to $560.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Weiss Ratings upgraded shares of Vertex Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Friday, July 17th. UBS Group increased their target price on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Finally, Sanford C. Bernstein dropped their price objective on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating for the company in a report on Tuesday, May 5th. Twenty-two research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $559.61.

Insider Activity at Vertex Pharmaceuticals

In related news, CMO Carmen Bozic sold 6,988 shares of the stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $450.00, for a total value of $3,144,600.00. Following the completion of the sale, the chief marketing officer owned 26,088 shares of the company’s stock, valued at approximately $11,739,600. This trade represents a 21.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $524.99, for a total value of $787,485.00. Following the transaction, the executive vice president owned 45,321 shares of the company’s stock, valued at approximately $23,793,071.79. This represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 17,452 shares of company stock valued at $8,103,997. 0.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Vertex Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Arrowstreet Capital Limited Partnership increased its holdings in Vertex Pharmaceuticals by 520.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 381,195 shares of the pharmaceutical company’s stock worth $149,291,000 after purchasing an additional 319,725 shares in the last quarter. Man Group plc lifted its position in shares of Vertex Pharmaceuticals by 184.3% during the 3rd quarter. Man Group plc now owns 362,774 shares of the pharmaceutical company’s stock valued at $142,077,000 after acquiring an additional 235,156 shares during the period. Alyeska Investment Group L.P. lifted its position in shares of Vertex Pharmaceuticals by 311.0% during the 3rd quarter. Alyeska Investment Group L.P. now owns 267,169 shares of the pharmaceutical company’s stock valued at $104,634,000 after acquiring an additional 202,169 shares during the period. Amundi boosted its stake in Vertex Pharmaceuticals by 16.6% during the fourth quarter. Amundi now owns 1,304,161 shares of the pharmaceutical company’s stock worth $591,254,000 after acquiring an additional 185,190 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Vertex Pharmaceuticals by 20.7% during the fourth quarter. Dimensional Fund Advisors LP now owns 945,660 shares of the pharmaceutical company’s stock worth $428,726,000 after acquiring an additional 162,074 shares in the last quarter. Institutional investors and hedge funds own 90.96% of the company’s stock.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Vertex reported second-quarter revenue of approximately $3.3 billion, up 12.45% year over year and slightly above Wall Street expectations. Operating profit reached about $1.2 billion, while operating cash flow rose to $1.4 billion. Vertex Reports Second Quarter 2026 Financial Results
• Positive Sentiment: The company raised its 2026 revenue outlook to $13.1 billion-$13.2 billion, above the roughly $13.0 billion consensus estimate, citing strong demand for its cystic fibrosis medicines. The higher forecast supports the view that Vertex’s core business remains resilient. Vertex raises annual revenue forecast on cystic fibrosis drugs strength
• Positive Sentiment: Growth is broadening beyond cystic fibrosis, with management highlighting momentum in sickle cell disease, beta thalassemia and acute pain. The pending Crinetics acquisition is expected to add rare endocrine diseases as another business platform.
• Positive Sentiment: Vertex’s partner CRISPR Therapeutics reported CASGEVY revenue of $76 million in the second quarter, up 151% year over year. FDA expansion of CASGEVY to children as young as two could enlarge the opportunity for the product, whose profits Vertex shares with CRISPR. CRISPR Therapeutics Reports Second Quarter 2026 Financial Results
• Neutral Sentiment: Analyst estimates for quarterly EPS vary slightly, but reported EPS of $4.73 was below consensus estimates of approximately $4.74-$4.79. Although EPS increased from $4.52 a year earlier, the miss may have disappointed investors given Vertex’s premium valuation. Vertex Pharmaceuticals Q2 Earnings Lag Estimates
• Negative Sentiment: Quiver Quantitative’s reported insider-trading data shows 50 insider sales and no purchases during the past six months. Such transactions can reflect routine compensation or tax planning, but the absence of insider buying may add to investor caution.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.